Dengue Vaccine Dengvaxia : World’s first dengue vaccine approved in over 10 countries

Review of:

Reviewed by:
Rating:
5
On October 4, 2016
Last modified:October 4, 2016

Summary:

Sanofi-Pasteur, the vaccines global business unit of Sanofi, announced today that the dengue vaccines have received approval in 14 countries.

First Dengue Vaccine : Dengue Vaccine Dengvaxia : Dengue Treatment : Dengue Treatment

Dengue Vaccine Dengvaxia : World’s first dengue vaccine

  • Sanofi-Pasteur, the vaccines global business unit of Sanofi, announced today that the dengue vaccines have received approval in 14 countries.
  • Following a number of countries–Mexico, Brazil, El Salvador, Costa Rica, Paraguay and the Philippines, the Singapore Health Sciences Authority (HSA) today approved the use of  vaccine, Dengvaxia.
  • The vaccine has been approved for use for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals aged 12 to 45 years.
  • Dengvaxia works like a “booster” that is more effective in protecting individuals who already have baseline immunity due to a previous dengue infection
Dengue Vaccine DengvaxiaDengue Vaccine Dengvaxia
  • The World Health Organization (WHO) does not recommend that countries implement a national vaccination program using Dengvaxia
  • When the population to be vaccinated has a prevalence of previous dengue infection below 50 percent.
  • “We’re pleased to see the growing medical and public health recognition for the vaccine,” Su Peing Ng, head of Global Medical Affairs for Sanofi Pasteur
  • WHO objectives for 50 per cent reduction in mortality and 25 per cent reduction in morbidity due to dengue by 2020
  • National medical societies in Indonesia, Brazil and Mexico recently also recommended vaccination with Dengvaxia, a company statement said.
Dengue Vaccine DengvaxiaDengue Vaccine Dengvaxia

  • In the clinical study population 9 years old and older, the dengue vaccine has been documented to prevent two-thirds of dengue cases due to all four serotypes of dengue.
  • The dengue vaccine also prevented 8 of 10 hospitalizations due to dengue and 93% of serious dengue cases like the deadly hemorrhagic form of the disease
  • Over the 25-month study follow-up period of the large-scale efficacy studies conducted in 10 endemic countries in Latin America and Asia.

 

THANKS FOR READING !

HELP TO IMPROVE US!

PLEASE GIVE SUGGESTIONS VIA COMMENTS!

READ  Maharashtra Buldhana Rape : 11 arrested for raping 12 minor tribal students

Loading...

Leave a Reply